Chronic treatment with human recombinant ...
|Title||Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice|
|Author(s)||J. M. Hengemihle, O. Abugo, J. Rifkind, Elizabeth Spangler, D. Danon, D. K. Ingram|
|Journal||Physiology & Behavior|
|Abstract||Erythropoietin is a glycoprotein produced endogenously in the kidney, which stimulates red blood cell production. We evaluated the effects of chronic treatment with recombinant human erythropoietin (epoetin alfa: EPO) on the performance of 6-month-old male C57BL/6J mice in a spatial learning task, the Morris water maze. Mice were treated with either EPO (1.5 U injected SC every other day) or vehicle (PBS also injected SC every other day). Results indicated that the treatment had no effect on maze performance after 8 weeks, but after 19 weeks the EPO-treated mice showed better performance compared to controls as measured by mean distance (centimeters) to reach the goal platform. The improved performance in EPO-treated mice at 19 weeks was accompanied by an increased hematocrit. After 32 wk of EPO-treatment, the hematocrit returned to baseline levels even though the size and density of the red blood cells were increased.|
Using APA 6th Edition citation style.
Times viewed: 264